Skip Navigation
 Nontuberculous Mycobacterial Lung Disease (NTM-LD)

Nontuberculous Mycobacterial Lung Disease (NTM-LD)

NTM (nontuberculous mycobacteria) and pseudomonas aeruginosa are types of bacteria found in the environment that can cause lung infections.  

These infections are more common in people with chronic lung conditions. Sputum cultures, high-resolution CT scans, and bronchoscopies are used to diagnose these infections. 

Treatment is sometimes long and difficult. Good hygiene, regular airway clearance, and avoiding smoking can help prevent these infections. 

NTM Lung Infections

What is NTM-LD?

Nontuberculous mycobacteria (NTM) are microorganisms found naturally in the environment. They can often be found in soil, lakes, rivers, and household water sources such as the water coming out of showerheads and faucets.

Most people breathe in or swallow small amounts of NTM organisms every day without getting sick. However, for some people, these organisms can settle in the lungs and cause infection. If left untreated, NTM-LD can become a chronic (long-lasting), progressive condition that may cause permanent lung damage.

The number of people diagnosed with NTM-LD is growing by 8% each year.1 The risk of NTM infection is significantly higher in people over the age of 65 and in women compared to men.2

Common Symptoms

Common Symptoms

NTM-LD typically develops gradually and presents symptoms similar to other lung conditions.2 Common symptoms include:

  • Chronic cough: A cough that will not go away, often producing mucus (sputum).
  • Changes in mucus: An increase in mucus production, or changes in color or thickness.
  • Fatigue: Feeling unusually tired or exhausted.
  • Weight loss: Losing weight without trying or by way of having a poor appetite.
  • Breathlessness: Feeling short of breath, especially during activity.
  • Fevers or night sweats: Occasional low-grade fevers or sweating while sleeping.

Who is at Higher Risk?

Anyone can get NTM-LD. It can be seen both in people without pre-existing lung disease, as well as those whose lungs have been damaged by other conditions, such as

  • Bronchiectasis
  • COPD
  • Asthma
  • Lung cancer
  • Cystic fibrosis
  • Alpha-1 antitrypsin deficiency

A weakened immune system (due to medications or other illnesses)3

Note: Some people with healthy lungs and no known risk factors can still develop NTM lung disease. Researchers are still working to understand why this happens.


Types of NTM

Although scientists have found nearly 200 NTM species that can cause NTM-LD, most NTM-LD in the United States is caused by mycobacterium avium complex (MAC) and, to a lesser extent, M. abscessus. They are often described by how fast they grow in the lab:4

  • Slow Growers: These take longer to show up in lab tests. The most common type is MAC. Others include M. kansasii and M. xenopi.
  • Rapid Growers: These grow more quickly in the lab. Common types include M. abscessus, M. chelonae, and M. fortuitum.

Note: Mycobacterial culture final results can take up to 6 to 8 weeks.


How NTM Lung Disease is Diagnosed

Diagnosing NTM-LD can be difficult because the organisms are found naturally in the environment. Health care professionals generally seek evidence that organisms are causing disease, rather than just present (i.e., a colonizer that does not require further evaluation or treatment). Diagnosis involves:

  • Medical history: A review of your symptoms and past health issues.
  • Imaging: High-resolution CT scan of your chest to look for specific patterns of lung damage.
  • Sputum cultures: You may be asked to provide several sputum (mucus) samples. These are tested with an acidfast‑ bacilli (AFB) smear and culture.
    • The AFB smear is a rapid test that can suggest active infection within 1–2 days. A positive test can suggest greater suspicion of a true infection.
    • Because NTM grow slowly, the culture results can take up to 6–8 weeks.6
  • Bronchoscopy (as needed): If a sputum sample is unable to be provided or if your sputum tests do not show NTM, but it is suspected, a bronchoscopy may be recommended.6

Note: Guidelines require at least two separate positive sputum samples to confirm if a person has NTM-LD.6

Management and Treatment

Management and Treatment

Management of NTM-LD is not one size fits all. Treatment plans are tailored specifically to you, your symptoms, and the specific type of organism found. Some people with NTM-LD may decide to wait before starting treatment. This is known as a “watch and wait” approach. In this case, your provider will closely monitor your lungs with regular check-ups and hold off on antibiotics but still address other management strategies, like airway clearance.

Patients need to think carefully about this choice, weighing the benefits of treatment against the risks and possible side effects of taking medication for a long time. Some benefits of starting treatment include better control of symptoms and slowing down damage to the lungs that cannot be reversed. Early treatment may be better tolerated and have less side effects. However, some patients might do well without treatment, leading to a decision in favor of “watchful waiting” for some.


  • Antibiotics: NTM-LD usually requires a combination of 3 to 4 antibiotics at the same time. Treatment may last around 18–24 months. Therapy generally continues for 12 months after getting negative sputum test results.3 These medicines can be taken as pills, nebulized antibiotics, or given through an IV (a tube inserted into a vein).
  • Airway clearance: Mucus can build up in the airways and become thick and sticky. This excess mucus can block the airways, lead to frequent coughing, and make it difficult to clear the lungs. If you have bronchiectasis, the airways can change shape, leading to even more mucus buildup. Airway clearing techniques help break up mucus, making it easier to clear. This can lessen shortness of breath, reduce coughing, and improve oxygen levels.7
  • Nutrition: Fighting lung infection requires great nutritional status. Many people with NTM-LD have a poor appetite; this can worsen weight loss and nutritional status.8 Talking to a registered dietitian or nutritionist can give you valuable insights to help meet nutritional needs.
  • Pulmonary rehabilitation and exercise: Pulmonary rehabilitation is a supervised program designed to improve fitness and strength with an exercise plan tailored to you. It can help you better manage low energy and shortness of breath, common in NTM-LD. The program also teaches breathing techniques, energy-saving tips, and provides education about your condition.8
  • Surgery: Surgery may be considered if the infection is severe, localized to just one area of the lung, and is not responding well to antibiotics.8

Ways to Reduce Exposure

Because NTM is found in water and soil, it cannot be avoided completely. However, you can lower the risk of inhaling or ingesting the organisms:

  • Avoid steam and mist: Stay away from hot tubs, spas, and indoor swimming pools where steam can carry the NTM organisms.
  • Turn up the heat: Set your water heater to more than 130°F (55°C) to help kill the organisms.
  • Choose safer showering: Consider taking baths instead of showers when possible. Use a large-droplet showerhead, consider soaking it regularly in bleach to reduce bacteria, and run the exhaust fan to minimize steam inhalation.11
  • Outdoor safety: Consider wearing a mask and wetting the soil while gardening to avoid breathing in dust and dirt.7

Note: While these steps are often recommended and may reduce exposure, there is limited clinical evidence that they ultimately reduce infection (or reinfection) risk.


Is NTM Contagious?

Unlike tuberculosis (mycobacterium tuberculosis), NTM-LD is generally not contagious and does not spread from person to person. However, in rare cases, specific types of NTM can spread between people who have cystic fibrosis.9


What to Expect with NTM-PD

If you have been diagnosed with NTM-LD, it’s important to seek care from an experienced pulmonologist or infectious disease specialist. Many people find that symptoms get better after starting medication, but NTM-LD can be difficult to completely cure. Treatment is often prolonged, sometimes lasting years.

The infection is considered adequately treated only when sputum culture samples remain free of NTM for at least 12 consecutive months.7 Even after successful treatment, there is a 40–50% risk of reinfection with the same or a different strain, so ongoing monitoring and lung care remain important.10

To help navigate NTM-LD with your care team, download the NTM Lung Disease Management Tool and other resources to guide conversations about diagnosis, symptom management, and treatment.

References:

  1. Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008-2015. Ann Am Thorac Soc. 2020;17(2):178-185. doi: 10.1513/AnnalsATS.201804-236OC
  2. Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. The Indian journal of medical research. September 2020. Accessed March 3, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC7881820/.
  3. Loebinger M, Quint J, Lann RV der, et al. Risk factors for nontuberculous mycobacterial pulmonary disease: A systematic literature review and meta-analysis. Chest. June 17, 2023. Accessed March 18, 2026. https://pubmed.ncbi.nlm.nih.gov/37429481/.
  4. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ers/escmid/IDSA clinical practice guideline. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. August 14, 2020. Accessed March 5, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC7768745/.
  5. Choi H, Chalmers JD. Bronchiectasis exacerbation: A narrative review of causes, risk factors, management and prevention. Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention. January 15, 2023. Accessed February 19, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC9906191/.
  6. Cowman S, Van Ingen J, Griffith DE, Loebinger M. European respiratory journal | european respiratory society. Non-tuberculous mycobacterial pulmonary disease. 2019. Accessed March 3, 2026. https://publications.ersnet.org/content/erj.
  7. Association AL. Diagnosing and treating NTM pulmonary disease. Diagnosing and Treating NTM Pulmonary Disease | American Lung Association. 2024. Accessed March 5, 2026. https://www.lung.org/lung-health-diseases/lung-disease-lookup/nontuberculous-mycobacteria/diagnosing-and-treating-ntm#:~:text=Raise%20the%20temperature%20of%20your,potting%20soil%20to%20reduce%20dust.
  8. Youssefnia A, Pierre A, Hoder JM, et al. Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: A narrative review. Journal of thoracic disease. September 2022. Accessed March 5, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC9562528/.
  9. Kumar K, Ponnuswamy A, Capstick TG, et al. Non-tuberculous mycobacterial pulmonary disease (NTM-PD): Epidemiology, diagnosis and multidisciplinary management. Clinical medicine (London, England). January 2024. Accessed March 9, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC11024839/.
  10. Boyle D, Zembower T, Qi C. Relapse versus reinfection of mycobacterium avium complex pulmonary disease. patient characteristics and macrolide susceptibility | annals of the American Thoracic Society. Annals of the American Thoracic Society. May 9, 2016. Accessed March 9, 2026. https://www.atsjournals.org/doi/10.1513/AnnalsATS.201605-344BC.
  11. Falkinham JO. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerging infectious diseases. March 2011. Accessed March 19, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC3166028/.

This page was reviewed on April 17, 2026 by the Bronchiectasis and NTM Association Content Review and Evaluation Committee.